These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 4734384)

  • 21. Alternative pathway of complement in sickle cell disease.
    Strauss RG; Asbrock T; Forristal J; West CD
    Pediatr Res; 1977 Apr; 11(4):285-9. PubMed ID: 846782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A serum factor in chronic hypocomplementemic hephritis distinct from immunoglobulins and activating the alternate pathway of complement.
    Vallota EH; Götze O; Spiegelberg HL; Forristal J; West CD; Müller-Eberhard HJ
    J Exp Med; 1974 May; 139(5):1249-61. PubMed ID: 4207623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms of immune lysis of red blood cells in vitro. I. Paroxysmal nocturnal hemoglobinuria cells.
    Logue GL; Rosse WF; Adams JP
    J Clin Invest; 1973 May; 52(5):1129-37. PubMed ID: 4700488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Host defense against opportunist microorganisms following trauma. II. Changes in complement and immunoglobulins in patients with abdominal trauma and in septic patients without trauma.
    Bjornson AB; Altemeier WA; Bjornson HS
    Ann Surg; 1978 Jul; 188(1):102-8. PubMed ID: 666370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factor B of the alternative complement pathway on human lymphocytes.
    Halbwachs L; Lachmann PJ
    Scand J Immunol; 1976; 5(6-7):697-704. PubMed ID: 824718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of anticomplementary substances on properdin in normal and C2-deficient sera.
    McLean RH; Townsend K; Michael AF
    Clin Exp Immunol; 1975 Mar; 19(3):435-44. PubMed ID: 1204244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Derivatives of the complement component MuB1 (C5mu) and separation of a factor involved in the conversion of MuB1 to MuB1f.
    Naylor DH; Cinader B
    Int Arch Allergy Appl Immunol; 1970; 39(5-6):540-65. PubMed ID: 4250087
    [No Abstract]   [Full Text] [Related]  

  • 28. Properdin factor D. II. Activation to D by properdin.
    Fearon DT; Austen KF; Ruddy S
    J Exp Med; 1974 Aug; 140(2):426-36. PubMed ID: 4211020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Studies of the alternate pathway in chelated serum.
    Forsgren A; Mclean RH; Michael AF; Quie PG
    J Lab Clin Med; 1975 Jun; 85(6):904-12. PubMed ID: 805816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Function of the classical and alternate pathways of human complement in serum treated with ethylene glycol tetraacetic acid and MgCl2-ethylene glycol tetraacetic acid.
    Des Prez RM; Bryan CS; Hawiger J; Colley DG
    Infect Immun; 1975 Jun; 11(6):1235-43. PubMed ID: 806523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complement alterations in inflammatory bowel disease.
    Lake AM; Stitzel AE; Urmson JR; Walker WA; Spitzer RE
    Gastroenterology; 1979 Jun; 76(6):1374-9. PubMed ID: 437435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The utilization of properdin in the alternate pathway of complement activation: isolation of properdin convertase.
    Stitzel AE; Spitzer RE
    J Immunol; 1974 Jan; 112(1):56-62. PubMed ID: 4130153
    [No Abstract]   [Full Text] [Related]  

  • 33. Anaphylatoxin in its relation to the complement system.
    Jensen J
    Science; 1967 Mar; 155(3766):1122-3. PubMed ID: 6021911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complement depletion with humanised cobra venom factor: efficacy in preclinical models of vascular diseases.
    Vogel CW; Fritzinger DC; Gorsuch WB; Stahl GL
    Thromb Haemost; 2015 Mar; 113(3):548-52. PubMed ID: 25031089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion.
    Maroko PR; Carpenter CB; Chiariello M; Fishbein MC; Radvany P; Knostman JD; Hale SL
    J Clin Invest; 1978 Mar; 61(3):661-70. PubMed ID: 641147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Major complement inhibiting factors from the venom of the Central Asian cobra Naja naja oxiana].
    Kozlov LV; Shoĭbonov BB; Antonov VK
    Biokhimiia; 1989 Nov; 54(11):1919-26. PubMed ID: 2627558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Studies of the C3 shunt activation in cobra venom induced lysis of unsensitized erythrocytes.
    Brai M; Osler AG
    Proc Soc Exp Biol Med; 1972 Jul; 140(3):1116-21. PubMed ID: 4625085
    [No Abstract]   [Full Text] [Related]  

  • 38. A starfish hemolymph factor which activates vertebrate complement in the presence of cobra venom factor.
    Day N; Geiger H; Finstad J; Good RA
    J Immunol; 1972 Jul; 109(1):164-7. PubMed ID: 4624674
    [No Abstract]   [Full Text] [Related]  

  • 39. Production of antibodies monospecifically reactive with the third component of guinea pig complement.
    Burkholder PM
    Int Arch Allergy Appl Immunol; 1970; 37(2):124-42. PubMed ID: 5411244
    [No Abstract]   [Full Text] [Related]  

  • 40. Association of activated properdin with complexes of properdin with C3.
    Whiteman LY; Purkall DB; Ruddy S
    J Immunol; 1991 Aug; 147(4):1344-51. PubMed ID: 1869827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.